Live feed03:30:00·4mPRReleasevia QuantisnowZealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetesByQuantisnow·Wall Street's wire, on your screen.ZEAL· Zealand Pharma A/SHealth Care
